公开(公告)号：US09938271B2

公开(公告)日：2018-04-10

申请号：US15119465

申请日：2015-02-13

申请人： VIIV HEALTHCARE UK (NO. 5) LIMITED

发明人： Kyle J. Eastman ,  John F. Kadow ,  B. Narasimhulu Naidu ,  Kyle E. Parcella ,  Kevin Peese

IPC分类号： C07D471/04 ,  C07D498/22

CPC分类号： C07D471/04 ,  C07D498/22

摘要： The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.

公开(公告)号：US10351546B2

公开(公告)日：2019-07-16

申请号：US15749584

申请日：2016-08-10

申请人： ViiV Healthcare UK (No. 5) Limited

发明人： Kyle J. Eastman ,  John F. Kadow ,  B. Narasimhulu Naidu ,  Kyle E. Parcella ,  Manoj Patel ,  Prasanna Sivaprakasam ,  Yong Tu

IPC分类号： A61K31/444 ,  C07D401/14 ,  C07D405/14 ,  C07D401/04 ,  C07D487/04 ,  A61P31/18 ,  A61K31/5365

摘要： Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV.

公开(公告)号：US10189816B2

公开(公告)日：2019-01-29

申请号：US15749176

申请日：2016-08-10

申请人： ViiV Healthcare UK (No.5) Limited

发明人： Kyle J. Eastman ,  John F. Kadow ,  Kyle E. Parcella ,  B. Narasimhulu Naidu ,  Tao Wang ,  Zhiwei Yin ,  Zhongxing Zhang

IPC分类号： A61K31/444 ,  C07D401/02 ,  C07D401/14 ,  C07D401/04 ,  A61P31/18 ,  A61K31/5365

摘要： Disclosed are compounds of Formula (I), including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS. In the compounds of formula (I), R1 is selected from hydrogen, alkyl, or cycloalkyl; R2 is selected from tetrahydroisoquinolinyl and is substituted with 1 R6 substituent and also with 0-3 halo or alkyl substituents; R3 is selected from azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, homopiperidinyl, homopiperazinyl, or homomorpholinyl, and is substituted with 0-3 substituents selected from cyano, halo, alkyl, haloalkyl, alkoxy, and haloalkoxy; R4 is selected from alkyl or haloalkyl; R5 is alkyl; R6 is selected from Ar1, (Ar1)alkyl, (chromanyl)alkyl, cyanocycloalkyl or (dihydrobenzodioxinyl)alkyl; and Ar1 is phenyl substituted with 0-5 substituents selected from cyano, halo, alkyl, cycloalkyl, haloalkyl, hydroxy, alkoxy, haloalkoxy, (hydroxy)alkoxy, (alkoxy)alkoxy, phenoxy, benzyloxy, carboxy, phenyl, and cyanocycloalkyl.

公开(公告)号：US10065953B2

公开(公告)日：2018-09-04

申请号：US15505955

申请日：2015-08-25

申请人： ViiV Healthcare UK (No.5) Limited

发明人： Timothy P. Connolly ,  Kyle J. Eastman ,  B. Narasimhulu Naidu ,  Kevin Peese

IPC分类号： C07D401/02 ,  C07D401/10 ,  A61K31/4353 ,  A61K31/437 ,  C07D471/04 ,  A61P31/18 ,  C07D519/00

CPC分类号： C07D471/04 ,  A61P31/18 ,  C07D519/00

摘要： The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.